remestemcel-L has NOT been rejected by the F
DA. A CRL is in fact "approved if you meet condition X". Unlike Regenaron it has a flawless safety profile. Regenaron is on a phase 1/2/3 trial and needs to meet the endpoints for each phase. It looks good so far, but is for a different stage of the disease and largely unrelated to us. It is not a revolutionary new way to treat inflammatory disease and therfore is indeed not in same league as MSB's products.
remestemcel-L has NOT been rejected by the FDA. A CRL is in fact...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |